-
Saracatinib (AZD0530) Applied Research Workflows
2026-09-04
Saracatinib (AZD0530) provides a practical way to interrogate Src/Abl-dependent proliferation, motility, and tumor signaling across complementary assay formats. This guide connects cancer-focused workflows with a carefully bounded neuroscience application inspired by Reelin–SFK research, while emphasizing controls, dose selection, and troubleshooting.
-
Chemotherapy Enhances Neoantigen T Cell Therapy
2026-09-04
The 2025 Cell Reports Medicine study identifies the KRAS.G12V-specific TCR T104 and shows that lymphodepleting chemotherapy can improve neoantigen presentation as well as T-cell-mediated tumor killing. Its mechanistic contribution is the connection between chemotherapy-induced immunoproteasome activity, increased HLA-I expression, and remodeling of the tumor immunopeptidome.
-
Cabazitaxel: Workflow Guide for Resistant Models
2026-09-03
Cabazitaxel (XRP6258, SKU B2157) is a semi-synthetic taxane derivative for studying microtubule dynamics disruption and antiproliferative responses in cancer cell models, including taxane-resistant systems. It should be prepared in DMSO or ethanol rather than water, stored as a solid at -20°C, and used promptly after solution preparation.
-
CX-4945 (Silmitasertib) Workflow Guide
2026-09-03
Build reproducible CK2 inhibition experiments with CX-4945 (Silmitasertib), from DMSO stock preparation through pathway, apoptosis, cell-cycle, and resistance readouts. The workflow connects product-level potency data with a lung cancer study that used CK2 inhibition to interrogate ECE-1c stability, stemness, cisplatin resistance, and invasion.
-
Sabutoclax: Pan-Bcl-2 Inhibitor Assay Guide
2026-09-02
Sabutoclax supports mechanism-focused cancer experiments that distinguish growth suppression from true apoptosis. Its broad Bcl-2 family coverage, membrane permeability, and activity in prostate, lung, and lymphoma models make it useful for concentration-response profiling, pathway validation, and translational assay design.
-
SLU-PP-332 and ERRα Agonists: A Focused Review
2026-09-02
This focused minireview positions SLU-PP-332 as a preclinical exercise mimetic that activates ERRα-linked transcriptional programs for mitochondrial biogenesis, fatty acid oxidation, and glucose regulation. Its main contribution is a balanced synthesis of mechanistic evidence, comparative ERR pharmacology, and translational barriers, especially the safety implications of pan-ERR activity and the lack of human data.
-
FOXL2–RhoA/ROCK Control of Granulosa Cell Shape
2026-09-01
A 2024 study in chicken pre-ovulatory follicles identifies a direct FOXL2–RhoA/ROCK axis that reorganizes granulosa-cell actin and regulates cell expansion. By combining FOXL2 ChIP-seq, gene perturbation, cytoskeletal analysis, and pharmacological pathway inhibition, the work connects a follicular transcription factor to a defined mechanism of cellular morphology.
-
10058-F4: c-Myc-Max Inhibition Workflows
2026-09-01
10058-F4 offers a small-molecule route to interrupt c-Myc/Max signaling and connect transcription-factor perturbation with apoptosis, differentiation, and tumor-model readouts. This practical guide covers dosing setup, orthogonal validation, AML and prostate cancer applications, and troubleshooting for reproducible experiments.
-
NAD+ and Energy Stress: Beyond Canonical Autophagy
2026-08-31
NAD+ research is moving beyond simple cofactor replacement toward a more precise view of redox balance, enzyme consumption, AMPK–ULK1 signaling, and stress recovery. This thought-leadership guide shows how translational researchers can use Nicotinamide Adenine Dinucleotide in mechanistically resolved metabolic and autophagy assays.
-
Glioblastoma Apoptotic Priming and BH3-Mimetics
2026-08-31
The reference study shows that glioblastoma, including patient-derived stem-like cells, is unusually dependent on anti-apoptotic BCL-xL and MCL-1 for survival. Its central translational insight is that sequential inhibition of these BCL-2 family proteins can produce strong antitumor responses in vivo without overt toxicity, highlighting apoptotic priming as a therapeutic vulnerability.
-
Anisomycin as a Causal Probe of JNK and Memory
2026-08-30
Anisomycin is a potent JNK agonist for dissecting stress signaling, apoptosis, and experimental causality. This guide connects JNK perturbation with neuroligin 1 proteolysis and social-memory maintenance while defining the limits of that cross-domain interpretation.
-
Alfuzosin HCl: Assay Workflows for BPH Research
2026-08-29
Alfuzosin HCl supports more than receptor pharmacology: it can anchor smooth-muscle experiments, micellar fluorescence assays, biological-matrix testing, and formulation release studies. This workflow-focused guide connects α1-receptor biology with practical preparation, validation, and troubleshooting decisions.
-
Genistein Workflows for Mechanotransduction and Cancer
2026-08-28
Genistein provides a controlled kinase-signaling perturbation for connecting growth-factor responses with cytoskeleton-dependent autophagy. This workflow separates pathway inhibition from solvent effects, mechanical loading, and cytotoxicity to support stronger cancer biology and mechanotransduction experiments.
-
Monkeypox Replication Inhibitors: Study Insights
2026-08-28
Chiem and colleagues identified 13 compounds that inhibited recombinant vaccinia virus and confirmed activity for 11 compounds against monkeypox virus in vitro, including Mubritinib (TAK 165). The study provides a practical reporter-based framework for repurposing antiviral candidates while emphasizing that hit confirmation, cytotoxicity testing, and mechanism-of-action studies remain essential.
-
Go 6983: Practical PKC Pathway Workflows
2026-08-27
Build reproducible PKC signaling experiments with Go 6983, from target-engagement assays to cancer and EMT models. A stage-aware extension also shows how this pan-PKC inhibitor can test, but not yet prove, links between PKC activity, WDR36-dependent glycolysis, and blastoid differentiation.